AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS ... discuss the array of existing and emerging classes of drugs that could benefit those with ACOS and share their ...

Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the ...

To address the growing concern about asthma, the Ministry of Public Health has launched a new awareness campaign aimed at ...

Company has also raised $12 million in funding led by Lucius Partners NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- AerWave Medical, a leader in ultrasound-based interventional pulmonary solutions, ...